FR941128-2-00085 FR941128-2-00046 6. The trustee shall use his or her best efforts to negotiate the most favorable price and terms available in each contract that is submitted to the Commission, subject to AHP's absolute and unconditional obligation to grant an exclusive license to Cyanamid's Rotavirus Vaccine Research as required by this Order at no minimum price. The exclusive license shall be made in the manner and to the Rotavirus Licensee as set out in this Order; provided, however, if the trustee receives bona fide offers from more than one acquiring entity, and if the Commission determines to approve more than one such acquiring entity, the trustee shall grant an exclusive license to the acquiring entity selected by Respondent from among those approved by the Commission. 7. The trustee shall serve, without bond or other security, at the cost and expense of AHP, on such reasonable and customary terms and conditions as the Commission or a court may set. The trustee shall have authority to employ, at the cost and expense of AHP, such consultants, accountants, attorneys, investment bankers, business brokers, appraisers and other representatives and assistants as are necessary to carry out the trustee's duties and responsibilities. After approval by the Commission and, in the case of a court-appointed trustee, by the court, of the account of the trustee, including fees for his or her services, all remaining monies shall be paid at the direction of AHP and the trustee's power shall be terminated. The trustee's compensation shall be based at least in significant part on a commission arrangement contingent on the trustee's ability to grant an exclusive license of Cyanamid's Rotavirus Vaccine Research. 8. Respondent shall indemnify the trustee and hold the trustee harmless against any losses, claims, damages, liabilities, or expenses arising out of, or in connection with, the performance of the trustee's duties, including all reasonable fees of counsel and other expenses incurred in connection with the preparations for, or defense of any claim whether or not resulting in any liability, except to the extent that such liabilities, losses, damages, claims, or expenses result from the misfeasance, gross negligence, willful or wanton acts, or bad faith by the trustee. 9. If the trustee ceases to act or fails to act diligently, a substitute trustee shall be appointed in the same manner as provided in Paragraph VI.A. of this Order. 10. The Commission or, in the case of a court-appointed trustee, the court, may on its own initiative or at the request of the trustee issue such additional orders or directions as may be necessary or appropriate to enter into the Rotavirus Exclusive License required by this Order. 11. The trustee shall have no obligation or authority to operate or maintain the Cyanamid Rotavirus Vaccine Research. 12. The trustee shall report in writing to AHP and to the Commission every sixty (60) days concerning the trustee's efforts to grant an exclusive license of Cyanamid's Rotavirus Vaccine Research as required by this Order. VII GM&hyph;CSF and IL&hyph;3 Royalties It is further ordered, That: A. Within thirty (30) days of the date on which the FDA approves any product that includes in whole or in part GM&hyph;CSF, as identified in the October 9, 1987 Technology Transfer and GM&hyph;CSF Supply Agreement between AHP and Sandoz, Ltd. (``GM&hyph;CSF Agreement''), AHP shall take such action as may be necessary to ensure that the royalty payments made pursuant to Section 10.2(b) of the GM&hyph;CSF Agreement and any reports of such payments are made on a worldwide aggregated basis. B. Within thirty (30) days of the date on which the FDA has approved both (1) any product that includes in whole or in part IL&hyph;3, as identified in the August 17, 1987 License Agreement for IL&hyph;3 between AHP and Sandoz, Ltd. (``IL&hyph;3 Agreement''); and (2) any product that includes in whole or in part Pixy321, also identified as rhIL&hyph;3/rhGM&hyph;CSF S. cerevisiae fusion protein, AHP shall take such action as may be necessary to ensure that the royalty payments made pursuant to Section 3.2 of the IL&hyph;3 Agreement and any reports of such payments are made on a worldwide aggregated basis. VIII Prior Approval It is further ordered, That, for a period of ten (10) years from the date this Order becomes final or until Respondent satisfies the requirements of Paragraphs II, III or IV, whichever is later, Respondent shall not without the prior approval of the Commission, directly or indirectly, through subsidiaries, partnerships, or otherwise: A. Acquire more than 1% of the stock, share capital, equity, or other interest in any concern, corporate or non-corporate, presently engaged in, or within the two years preceding such acquisition engaged in, the (1) clinical development or (2) manufacture and sale of tetanus or diphtheria vaccines in the United States;
